Company News-宜明昂科英文

Company News

Company News

Company News

ImmuneOnco and Instil Bio Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, IMM2510/SYN-2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Dallas, Texas, and Shanghai, China, Sep. 16, 2024 – Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).

Further payment received under the license and collaboration agreement with SynBioTx for IMM2510 and IMM27M

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo

Upfront payment received under the license and collaboration agreement with SynBioTx for IMM2510 and IMM27M

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the“Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential investo

ImmuneOnco and Instil Bio Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Shanghai, China and Dallas, TX, August 01, 2024 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”) and Instil Bio, Inc. (Nasdaq: TIL, “Instil”), today announced a defin

First Patient In and Dosing completed in Phase III Clinical Trial of Timdarpacept (IMM01) combined with Tislelizumab for cHL patient refractory to PD-(L)1 therapy

On July 3, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that Timdarpacept (IMM01) combined with Tislelizumab for refractory cHL Phase III clinical trial successfully completed the first patient enrollment on July 1, 2024.

The Phase Ib clinical trial of IMM0306 in combination with lenalidomide for relapsed/refractory DLBCL completed the first patient enrollment

On April 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK) announced that the Phase Ib clinical trial of IMM0306 in combination with len

总计 53 12 3 4 5 6 7 8 9